0001520138-19-000143.txt : 20190510 0001520138-19-000143.hdr.sgml : 20190510 20190510152540 ACCESSION NUMBER: 0001520138-19-000143 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 41 CONFORMED PERIOD OF REPORT: 20190331 FILED AS OF DATE: 20190510 DATE AS OF CHANGE: 20190510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55292 FILM NUMBER: 19814608 BUSINESS ADDRESS: STREET 1: 11601 WILSHIRE BLVD. STREET 2: SUITE 1100 CITY: LOS ANGELES STATE: CA ZIP: 90025 BUSINESS PHONE: 312-283-5793 MAIL ADDRESS: STREET 1: 11601 WILSHIRE BLVD. STREET 2: SUITE 1100 CITY: LOS ANGELES STATE: CA ZIP: 90025 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 10-Q 1 bivi-20190331_10q.htm FORM 10-Q FOR PERIOD ENDING MARCH 31, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2019

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to _____________

Commission File Number: 000-55292

BIOVIE INC.

(Exact name of registrant as specified in its charter)

Nevada		46-2510769
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

11601 Wilshire Blvd Suite 1100

Los Angeles, CA 90025

(Address of principal executive offices, Zip Code)

(312)-283-5793

(Registrant's telephone number, including area code)

(Former Name, Former Address and Former Fiscal Year if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of shares outstanding of each of the issuer’s classes of common equity, as of May 10, 2019 was 316,453,673.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	1
	Condensed Balance Sheets as of March 31, 2019 (unaudited) and June 30, 2018	1
	Condensed Statements of Operations (unaudited) - for the three months and nine months ended March 31, 2019 and 2018	2
	Condensed Statements of Cash Flows (unaudited) - for the nine months ended March 31, 2019 and 2018	3
	Condensed Statements of Changes in Stockholders’ Equity (unaudited) - for the period from July 1, 2017 through March 31, 2018 and from July 1, 2018 through March 31, 2019	4
	Notes to Unaudited Condensed Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4.	Controls and Procedures	19

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	20
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3.	Defaults Upon Senior Securities	20
Item 4.	Mine Safety Disclosures	20
Item 5.	Other Information	20
Item 6.	Exhibits	21

SIGNATURES		22

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie Inc.

BioVie Inc.

Condensed Balance Sheets

	March 31,			June 30,
	2019			2018*
ASSETS	(Unaudited)

CURRENT ASSETS:
Cash	$	971,614		$	45,800
Other Assets		35,000			—
Total Current Assets		1,006,614			45,800

OTHER ASSETS:
Intangible Assets, Net		1,611,947			1,783,980
Goodwill		345,711			345,711
Total Other Assets		1,957,658			2,129,691

TOTAL ASSETS	$	2,964,272		$	2,175,491

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Accounts Payable and accrued expenses	$	179,054		$	884,207
Accrued Payroll		—			354,167
Total Current Liabilities		179,054			1,238,374

LONG-TERM LIABILITIES:
Demand Promissory Note		—			250,000
Notes Payable, Related Parties		—			575,918
Total Long-Term Liabilities		—			825,918

TOTAL LIABILITIES		179,054			2,064,292

Commitments and contingencies (Note 7)

STOCKHOLDERS' EQUITY

Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding		—			—
Common stock, $0.0001 par value; 800,000,000 and 300,000,000 shares authorized at March 31, 2019 and June 30, 2018, respectively; 316,453,673 and 98,503,199 shares issued and outstanding at March 31, 2019 and June 30, 2018, respectively		31,645			9,850
Additional paid in capital		9,359,780			4,870,475
Accumulated deficit		(6,606,207	)		(4,769,126	)
Total Stockholders' Equity		2,785,218			111,199

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	2,964,272		$	2,175,491

*Derived from audited balance sheet as of June 30, 2018

See accompanying notes to unaudited condensed financial statements

-1-

Table of Contents

BioVie Inc.

Condensed Statements of Operations

(Unaudited)

	Three Months			Three Months			Nine Months			Nine Months
	Ended			Ended			Ended			Ended
	March 31,			March 31,			March 31,			March 31,
	2019			2018			2019			2018

REVENUE	$	—		$	—		$	—		$	—

OPERATING EXPENSES:
Amortization		57,344			57,344			172,033			172,033
Research and development expenses		331,834			46,420			732,373			275,116
Selling, general and administrative expenses		459,111			587,450			936,180			1,401,104
TOTAL OPERATING EXPENSES		848,289			691,215			1,840,586			1,848,253

LOSS FROM OPERATIONS		(848,289	)		(691,215	)		(1,840,586	)		(1,848,253	)

OTHER EXPENSE (INCOME):
Other income		—			—			(51,400	)		—
Interest expense		—			1,342			272			9,828
Interest income		(248	)		—			(1,036	)		(1	)
TOTAL OTHER EXPENSE (INCOME), NET		(248	)		1,342			(52,164	)		9,827


NET LOSS	$	(848,041	)		(692,557	)	$	(1,788,422	)	$	(1,858,080	)

Deemed dividend related to ratchet adjustment		—			—			48,659			—

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(848,041	)	$	(692,557	)	$	(1,837,081	)	$	(1,858,080	)

NET LOSS PER SHARE BASIC AND DILUTED	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.02	)

WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING BASIC AND DILUTED		316,422,562			96,939,603			313,580,066			95,014,206

See accompanying notes to unaudited condensed financial statements

-2-

Table of Contents

BioVie Inc.

Condensed Statements of Cash Flows

(Unaudited)

	Nine Months Ended			Nine Months Ended
	March 31, 2019			March 31, 2018

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(1,788,422	)	$	(1,858,080	)
Adjustments to reconcile net loss to net cash to cash used in operating activities:
Common shares issued for service		49,000			—
Amortization of intangible assets		172,033			172,033
Stock based compensation expense		63,306			811,203
Gain on settlement of debt		51,400			—
Changes in operating assets and liabilities
Other assets		(35,000	)		—
Accounts payable and accrued expenses		(382,203	)		275,283
Accrued payroll		—			187,500
Net cash used in operating activities		(1,869,886	)		(412,061	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt		(244,300	)		(10,000	)
Proceeds from issuance of preferred shares		3,040,000			—
Proceeds from issuance of common stock and warrants		—			445,001
Net cash provided by financing activities		2,795,700			435,001

Net increase in cash		925,814			22,940

Cash, beginning of period		45,800			5,140

Cash, end of period	$	971,614		$	28,080

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	—		$	—
Cash paid for taxes	$	—		$	—

SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Conversion of preferred shares to common stock	$	3,200,000		$	—
Settlement of debt by issuance of common stock and forgiveness of debt	$	1,150,135		$	—
Cashless exercise of warrants	$	224		$	—
Deemed dividends for ratchet adjustments to warrants	$	48,659		$	—

See accompanying notes to unaudited condensed financial statements

-3-

Table of Contents

BioVie Inc.

Condensed Statements of Stockholders’ Equity

(Unaudited)

	Preferred			Preferred			Common		Common		Additional						Total
	Stock			Stock			Stock		Stock		Paid in			Accumulated			Stockholders'
	Shares			Amount			Shares		Amount		Capital			Deficit			Equity
Balance, June 30, 2017		—		$	—			91,925,000	$	9,193	$	3,483,134		$	(2,335,009	)	$	1,157,318

Issuance of shares in a private placement		—			—			1,169,091		117		244,883			—			245,000

Issuance of shares for services		—			—			1,500,000		150		329,850			—			330,000

Stock option compensation		—			—			—		—		12,752			—			12,752

Net loss		—			—			—		—		—			(662,841	)		(662,841	)

Balance, September 30, 2017 (Unaudited)		—			—			94,594,091		9,460		4,070,619			(2,997,850	)		1,082,229

Issuance of shares in a private placement		—			—			227,273		23		49,977			—			50,000

Issuance of shares for services		—			—			150,000		15		34,485			—			34,500

Issuance of warrants in a private placement		—			—			—		—		100,000			—			100,000

Stock option compensation		—			—			—		—		27,021			—			27,021

Net loss		—			—			—		—		—			(502,682	)		(502,682	)

Balance, December 31, 2017 (Unaudited)		—			—			94,971,364		9,498		4,282,102			(3,500,532	)		791,068

Issuance of shares in a private placement		—			—			333,333		33		49,967			—			50,000

Stock option compensation		—			—			—		—		152,062			—			152,062

Issuance of shares for services		—			—			2,030,000		203		242,197			—			242,400

Issuance of warrants for services		—			—			—		—		12,469			—			12,469

Net loss		—			—			—		—		—			(692,557	)		(692,557	)

Balance, March 31, 2018 (Unaudited)		—		$	—			97,334,697	$	9,734	$	4,738,797		$	(4,193,089	)	$	555,442

Balance, June 30, 2018		—		$	—			98,503,199	$	9,850	$	4,870,475		$	(4,769,126	)	$	111,199

Issuance of preferred stock in a private placement		2,133,332			3,200,000			—		—		3,200,000			—			3,200,000

Conversion of preferred stock to common stock		(2,133,332	)		(3,200,000	)		213,333,200		21,333		(21,333	)		—			—

Issuance of shares in exchange for debt settlement		—			—			975,361		98		1,150,037			—			1,150,135

Stock option compensation		—			—			—		—		3,412			—			3,412

Cashless exercise of warrants		—			—			2,241,913		224		(224	)		—			—

Deemed dividends for ratchet adjustment to warrants		—			—			—		—		48,659			(48,659	)		—

Net loss		—			—			—		—		—			(439,871	)		(439,871	)

Balance, September 30, 2018 (Unaudited)		—			—			315,053,673		31,505		9,251,026			(5,257,656	)		4,024,875

Stock option compensation		—			—			—		—		16,285			—			16,285

Net loss		—			—			—		—		—			(500,510	)		(500,510	)

Balance, December 31, 2018 (Unaudited)		—			—			315,053,673		31,505		9,267,310			(5,758,166	)		3,540,650

Stock option compensation		—			—			—		—		43,609			—			43,609

Issuance of shares for services								1,400,000		140		48,860						49,000

Net loss		—			—			—		—		—			(848,041	)		(848,041	)

Balance, March 31, 2019 (Unaudited)		—		$	—			316,453,673	$	31,645	$	9,359,780		$	(6,606,207	)	$	2,785,218

See accompanying notes to unaudited condensed financial statements

-4-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

1.	Background Information

BioVie Inc. (the “Company”) is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. The Company began dosing patients with BIV201 in September 2017 at the McGuire Research Institute Inc. in Richmond, VA. All six of the planned patients have been treated with BIV201 therapy in this Phase 2a clinical trial. In May 2019, the Company announced that the primary study objectives to assess the safety, tolerability, and pharmacokinetics (PK) of a continuous infusion of terlipressin over 28 days had been achieved. Detailed results will be presented to the Food & Drug Administration (“FDA”) in the first half of 2019.

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites. The Company has secured a US Patent covering the use of BIV201 for the treatment of ascites patients in the outpatient setting using ambulatory pump infusion, and has filed patent applications for its product candidate in Japan, and Europe, Hong Kong, and China. BIV201 also received Orphan Drug designation for hepatorenal syndrome (“HRS”) in November 2018.

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp.’s rights to our program remain unchanged.

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company’s business plan.

2.	Liquidity and Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has experienced losses since inception and has an accumulated deficit of approximately $6.6 million at March 31, 2019. In addition, the Company has not generated any revenues and no revenues are anticipated in the foreseeable future. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization efforts, as well as continuing to secure additional financing.

-5-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

2.	Liquidity and Going Concern (continued)

In July 2018, the Company completed a capital raise from Acuitas Group Holdings, LLC (“Acuitas”) and other purchasers and received net proceeds of $3.2 million and has resumed further clinical development of BIV201. The Acuitas investment agreement also stipulated that if the clinical development of BIV201 continues, Acuitas may at its option invest up to an additional $3 million to fund operations in year two, less any federal or FDA grant funding received by the Company.

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

3.	Significant Accounting Policies

Basis of Presentation – Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018.

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018.

Net Loss per Common Share

Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.

-6-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

3.	Significant Accounting Policies (continued)

The table below shows the number of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:

	March 31, 2019		June 30, 2018
	Number of Shares		Number of Shares
Stock Options		7,250,000		5,150,000
Warrants		216,440,548		4,774,015
Total		223,690,548		9,924,015

Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the financial statements.

-7-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

4. Intellectual Property

Intellectual property, stated at cost, less accumulated amortization consists of the following:

	March 31, 2019		June 30, 2018

Intellectual Property	$	2,293,770	$	2,293,770
Accumulated Amortization		681,823		509,790
Intellectual Property, Net	$	1,611,947	$	1,783,980

Amortization expense for the three- and nine-month periods ended March 31, 2019 and 2018 was $57,344 and $172,033, respectively. Estimated future amortization expense is as follows:

Year ending June 2019 (remaining three months)	$ 57,344
2020	229,377
2021	229,377
2022	229,377
2023	229,377
Thereafter	637,095
	$ 1,611,947

5. Renegotiated Debt

On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000 and received cash of $65,000 and 260,000 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $51,400 on the settlement of debt was reflected on the Statements of Operations as “other income” for the nine-month period ended March 31, 2019.

-8-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

6. Related Party Transactions

On July 9, 2018, Jonathan Adams (COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital.

On July 9, 2018, Elliot Ehrlich (former CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,273 and 222,028 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital.

On August 8, 2018, Barrett Ehrlich (Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (“Barrett”) entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting fees, totaling $543,014, and received cash of $131,333 and 493,333 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.13 per common share. The gain of $361,548 on the settlement of debt was reflected in the additional paid in capital.

See note 8 for other related party transactions.

7. Commitments and Contingencies

Office Lease

On October 1, 2018, the Company executed a lease agreement with Acuitas Group Holdings, LLC (related party) for the Company’s office at 11601 Wilshire Blvd Ste 1100, Los Angeles, CA 90025. The lease is a month-to-month lease that may be cancelled upon 30 days’ written notice and requires monthly payments of $1,000.

Challenge to US Patent

On April 30, 2018, the Company received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of BioVie’s US Patent No. 9,655,945 titled “Treatment of Ascites” (the ‘945 patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.

-9-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

7. Commitments and Contingencies (continued)

On August 15, 2018, BioVie submitted a Preliminary Response to the PTAB providing a rationale as to why, in the Company’s opinion, Mallinckrodt’s request to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable likelihood of success in proving that at least one of the Company’s 14 claims was unpatentable. On March 7, 2019, we submitted a Patent Owner’s Response and a Patent Owner’s Contingent-Motion to Amend our patent claims, and Declaration of Dr. Jaime Bosch, MD, PhD, our medical expert. We are actively defending the ‘945 patent and may explore the possibility of settlement with Mallinckrodt. However, there can be no assurance in that a favorable outcome will result, or if settlement is reached that the PTAB will accept it. Although the PTAB encourages settlement, in view of public-interest considerations, the board may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due to settlement, the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019. As of March 31, 2019, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time.

Royalty Agreements

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation; and The Barrett Edge, Inc.

The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.

-10-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

8. Equity Transactions

Stock Options

The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2019:

	Options		Weighted-Average Exercise Price		Weighted Remaining Average Contractual Term		Aggregate Intrinsic Value
Outstanding at June 30, 2018		5,150,000	$	0.12		5.8	$	—
Granted		2,100,000	$	0.04		4.6	$	88,370
Options Exercised or Forfeited		—	$	—		—	$	—
Outstanding at March 31, 2019		7,250,000	$	0.10		5.3	$	166,175
Exercisable at March 31, 2019		6,250,000	$	0.10		5.3	$	—

The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option – Pricing model reflecting the following weighted-average assumptions:

	March 31,
	2019			2018
Expected life of options (In years)		5			5
Expected volatility		69.77	%		69.66	%
Risk free interest rate		2.60	%		1.59	%
Dividend Yield		0	%		0	%

Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.

The Company recorded stock-based compensation expense of $43,609 and $63,306 for the three-and nine-month periods ended March 31, 2019, respectively, and $152,062 and $191,835 for the three-and nine-month periods ended March 31, 2018, respectively.

-11-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

8. Equity Transactions (continued)

The fair value of options vested during the nine-month period ended March 31, 2019 and 2018, was $10,235 and $25,281 respectively.

As of March 31, 2019, there was approximately $1,555 of unrecognized compensation cost related to non-vested options granted which is expected to be recognized over a weighted-average period of 1 months.

The following is a summary of stock options outstanding and exercisable by exercise price as of March 31, 2019:

				Weighted Average
Exercise Price		Outstanding		Contract Life		Exercisable
$	0.03		700,000		4.8		700,000
$	0.05		1,300,000		4.6		1,300,000
$	0.06		3,100,000		6.9		2,100,000
$	0.07		100,000		4.5		100,000
$	0.10		500,000		3.8		500,000
$	0.20		200,000		3.5		200,000
$	0.21		550,000		3.1		550,000
$	0.22		100,000		3.0		100,000
$	0.23		200,000		3.4		200,000
$	0.25		500,000		2.6		500,000
	Total		7,250,000				6,250,000

Offerings of Common Stock and Warrants

Issuance of Shares for Cash

On July 3, 2018, BioVie Inc., the Company, entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company’s newly created Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) the Company will issue associated warrants (the “Warrants”) to purchase 213,333,200 shares of the Company’s Class A Common Stock (the “Common Stock”), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The Company received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that the Company has not obtained $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale.

-12-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

8. Equity Transactions (continued)

Each share of Preferred Stock automatically converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to the Company’s Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of the Company’s issued and outstanding Common Stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of the Company’s Definitive Information that was filed with the Securities and Exchange Commission.

The purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment. In the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of the Company’s current intellectual property rights being reduced by more than 75 percent, then the price per share of Common Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for example, if the then-effective price per share of Common Stock is $0.015, then following such event, the price per share will be $0.0075). In this case, the Company may be required to issue additional shares of Common Stock, but in no event will the Company be required to pay cash, to reflect such lower price per share.

The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, the Company also disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals Ireland Limited petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the Company’s obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company’s obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and (v) certain recent issuances of Common Stock by the Company.

Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company’s Board of Directors (the “Board”) and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act.

-13-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

8. Equity Transactions (continued)

Issuance of Shares for Services

On January 2, 2019, the Company issued 1,400,000 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $0.035 per share.

Issuance of Shares in Settlement of Debt

During the nine months ended March 31, 2019, the Company settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 975,361 shares of common stock with a fair value of $1,150,135. See notes 5 and 6.

Issuance of Stock Options

On October 1, 2018, the Company issued stock options to purchase 100,000 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $0.07 at any time from date of issuance and expire in 5 years from the date of issuance.

On October 13, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.

On October 27, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance

On November 10, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options are exercisable at an exercise price of $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.

On January 19, 2019, the Company issued stock options to purchase 100,000 shares of common stock to each of five key employees or consultants and two company directors as part of his or her annual compensation, for an aggregate total of 700,000 stock options. The stock options are exercisable at an exercise price of $0.025 at any time from date of issuance until 5 years from the date of issuance.

On March 11, 2019, the Company issued stock options to purchase 1,000,000 shares of common stock to an investor relations (IR) consultant. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance.

Cashless exercise of warrant

On August 4, 2018, the Company issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares at an exercise price of $0.015 per share. As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise of warrants to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share.

-14-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Nine Months Ended March 31, 2019 and 2018

(unaudited)

8. Equity Transactions (continued)

Warrant Price Adjustment

In December 2017, the Company issued warrants to purchase 2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000. The warrants were exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In January 2018, the Company sold shares at $0.15, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $20,995 as a deemed dividend. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.

In January 2018, the Company issued warrants to purchase 210,000 shares of common stock in exchange for banking services which was recognized at fair value. The warrants were exercisable at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method.

The following table summarizes the warrants that have been issued:

				Weighted		Weighted Average		Aggregate
	Number of Shares			Average Exercise Price		Remaining Life (Years)		Intrinsic Value
Outstanding at June 30, 2018		4,774,015		$	0.29		5.5	$	—
Granted		214,166,533		$	0.02		5.3	$	14,284,908
Expired		—		$	—		—	$	—
Exercised		(2,500,000	)	$	0.02		—	$	—
Outstanding and exercisable at March 31, 2019		216,440,548		$	0.03		5.3	$	14,284,908

Of the above warrants, 1,173,864 expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 214,709,866 expire in fiscal year ending June 30, 2025.

9. Subsequent Events

In April 2019, to facilitate the Company’s planned uplisting to the NASDAQ Stock Market and related potential future issuances and sales of equity securities for ordinary corporate finance and general corporate purposes and as recommended by the Board of Directors (“Board”), the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation to effect a reverse split of its outstanding Class A common stock in the range of 50:1 to 200:1, as determined by the Board. Following that approval, the Company filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the “S-1 Registration Statement”) pursuant to which it anticipates completing an offering of equity securities with proceeds sufficient to enable the launch and completion of the BIV201 Phase 2b study and fund internal operations for at least the next twelve months.

-15-

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our; research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

The following discussion of the Company’s financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company’s other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company’s fluctuations in sales, expenses and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (f) pending litigation.

Management’s Discussion

BioVie is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies targeting life-threatening complications of liver cirrhosis. Our initial disease target is ascites, a serious medical condition affecting about 100,000 Americans and many times more worldwide. Our therapeutic drug candidate BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. The active agent in BIV201, terlipressin, is a potent vasoconstrictor which is in use for various medical conditions around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

-16-

Table of Contents

Comparison of the three months ended March 31, 2019 to the three months ended March 31, 2018

Total operating expenses for the three months ended March 31, 2019 were $848,000 compared to $691,000 for the three months ended March 31, 2018. The net increase of $157,000 was primarily due to a $285,000 increase in research and development expenses due to the timing of clinical trials, offset by a $128,000 reduction in selling, general and administrative expenses due to the issuance of common stock in January 2018 as compensation for professionals.

Research and Development Expenses

Research and development expenses were $332,000 for the three months ended March 31, 2019, an increase of $286,000, from $46,000 for the three months ended March 31, 2018. The increase was primarily attributed to the timing of clinical trials.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $459,000 for the three months ended March 31, 2019, a decline of $128,000, compared to $587,000 for the three months ended March 31, 2018. In January 2018, the Company paid for professional fees with BioVie common stock.

Comparison of the nine months ended March 31, 2019 to the nine months ended March 31, 2018

Total operating expenses for the nine months ended March 31, 2019 were $1,841,000 compared to $1,848,000 for the nine months ended March 31, 2018. The net decrease of $7,000 was primarily due to a $465,000 reduction in selling, general and administrative expenses due to the issuance of common stock in August 2017 and January 2018 as compensation for professionals, offset by the increase in research and development expenses of $457,000 as the Company resumed its clinical trial program and hired 1 full time employee and 1 half time employee in November 2018, which were previously consultants.

Research and Development Expenses

Research and development expenses were $732,000 for the nine months ended March 31, 2019, an increase of $457,000, from $275,000 for the nine months ended March 31, 2018. The increase was primarily attributed to continued analytical research and associated regulatory and clinical trial program planning and the Phase 2a clinical trial activities which began in July 2018.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $936,000 for the nine months ended March 31, 2019, a decline of $465,000, from $1,401,000 for the nine months ended March 31, 2018. In August 2017 and January 2018, the Company paid for professional fees related to financial and strategic advisory services with BioVie common stock.

Capital Resources and Liquidity

The Company completed a capital raise of $3.2 million in July 2018 which enabled the Company to resume and further develop its products. At March 31, 2019 the Company had $972,000 of cash to complete its Phase 2a clinical trial of the BIV201 therapy and initiate a planned Phase 2b clinical trial. As further discussed below, the Company is pursuing various options to raise further financing to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b Clinical trial until sufficient funding is secured.

As of March 31, 2019, the Company had an accumulated deficit of $6.6 million and as a development stage enterprise, the Company expects substantial losses in future periods. The accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

-17-

Table of Contents

In July 2018 we completed a capital raise from Acuitas Group Holdings, LLC (“Acuitas”) and other purchasers and received gross proceeds of $3.2 million and has resumed to further clinical development of BIV201. The Acuitas investment agreement also stipulated that if the clinical development of BIV201 continues, Acuitas may invest an additional $3 million to fund operations in year two, less any federal or FDA grant funding received by the Company.

We cannot assure you that our drug candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues sufficient to support our operations or that we will ever be profitable. Furthermore, since we have no committed source of financing, we cannot assure you that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations.

Additionally, in April 2019, to facilitate our planned uplisting to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (“Board”), our stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common stock in the range of 50:1 to 200:1, as determined by our Board. Following that approval, we filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the “S-1 Registration Statement”) pursuant to which we anticipate completing an offering of our equity securities with proceeds sufficient to enable the launch and completion of the BIV201 Phase 2b study and fund our internal operations for at least the next twelve months. There can be no assurance, however, that we will achieve effectiveness of the S-1 Registration Statement or successfully complete an offering thereunder.

Management intends to attempt to secure additional required funding primarily through additional equity or debt financings. We may also seek to secure required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to co-develop and fund research and development efforts, or similar transactions. However, there can be no assurance that we will be able to obtain required funding. If we are unsuccessful in securing funding from any of these sources, we will defer, reduce or eliminate certain planned expenditures in our research protocols. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us.

These circumstances raise substantial doubt on our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Critical Accounting Policies and Estimates

For the nine-month period ended March 31, 2019, there were no significant changes to the Company’s critical accounting policies as identified in the Annual Report Form 10-K for the fiscal year ended June 30, 2018.

New Accounting Pronouncements

The Company considered the applicability and impact of recent accounting pronouncements and determined those to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

-18-

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable

Item 4. Controls and Procedures

We maintain “disclosure controls and procedures,” such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulate and communicated to our management, including our Chief Executive Office and Chief Financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgement in evaluating the cost-benefit relationship of possible disclosure and procedures. The design of and disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based upon their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15f and 15d-15(f) under the Exchange Act), that occurred during the quarter ended March 31, 2019 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

-19-

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

To our knowledge, neither the Company nor any of our officers or directors is a party to any material legal proceeding or litigation and such persons know of no material legal proceeding or contemplated or threatened litigation, other than as set forth below:

On April 30, 2018, we received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of our US Patent No. 9,655,945 titled “Treatment of Ascites” (the ‘945 patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications. On August 15, 2018, we submitted a Preliminary Response to the PTAB providing a rationale as to why, in our opinion, Mallinckrodt’s request to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable likelihood of success in proving that at least one of our 14 claims was unpatentable. On March 7, 2019, we submitted a Patent Owner’s Response and a Patent Owner’s Contingent-Motion to Amend our patent claims, and Declaration of Dr. Jaime Bosch, MD, PhD, our medical expert. We are actively defending the ‘945 patent and may explore the possibility of settlement with Mallinckrodt. However, there can be no assurance in that a favorable outcome will result, or if settlement is reached that the PTAB will accept it. Although the PTAB encourages settlement, in view of public-interest considerations, the board may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due to settlement, the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019.

There are no judgments against us or our officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance in corporate office.

Item 2. Unregistered sales of equity securities

During the three months ended March 31, 2019, we issued the following securities that were not registered under the Securities Act:

On March 11, 2019, the Company issued stock options to purchase 1,000,000 shares of Class A common stock to an investor relations (IR) consultant. The stock options are exercisable at $0.05 at any time and expire 5 years from the date of issuance. The stock options were issued in reliance upon Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering.

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

None

-20-

Table of Contents

Item 6. Exhibits

(a) Exhibit index

Exhibit

31.1*		Certification of Chief Executive Officer (Principal Executive Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
31.2*		Certification of Chief Financial Officer (Principal Financial Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
31.1**		Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

*	Filed herewith.

**	Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

-21-

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioVie Inc.,


Signature	Titles	Date

/s/ Terren Peizer ________________ Terren Peizer	Chairman and Chief Executive Officer (Principal Executive Officer)	May 10, 2019
/s/ Joanne Wendy Kim _________________ Joanne Wendy Kim	Chief Financial Officer	May 10, 2019

-22-

EX-31.1 2 bivi-20190331_10qex31z1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

CERTIFICATION

I, Terren Peizer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Biovie, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.		The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2019

								/s/ Terren S. Peizer
								Terren S. Peizer Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 bivi-20190331_10qex31z2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

CERTIFICATION

I, Joanne Wendy Kim, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Biovie, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.		The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2019

/s/ Joanne Wendy Kim

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 4 bivi-20190331_10qex32z1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Biovie, Inc., (the “Company”) on Form 10-Q for the period ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Terren Peizer, Chief Executive Officer and Chairman of the Board of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2019

								/s/ Terren S. Peizer
								Terren S. Peizer Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 bivi-20190331_10qex32z2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Biovie, Inc., (the “Company”) on Form 10-Q for the period ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joanne Wendy Kim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2019

/s/ Joanne Wendy Kim

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-101.INS 6 bivi-20190331.xml XBRL INSTANCE FILE 0001580149 2017-06-30 0001580149 2019-05-10 0001580149 2018-07-01 2019-03-31 0001580149 2018-06-30 0001580149 us-gaap:CommonStockMember 2019-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001580149 us-gaap:RetainedEarningsMember 2019-03-31 0001580149 2017-07-01 2018-03-31 0001580149 2018-03-31 0001580149 us-gaap:StockOptionMember 2017-07-01 2018-06-30 0001580149 us-gaap:WarrantMember 2017-07-01 2018-06-30 0001580149 us-gaap:StockOptionMember 2019-03-31 0001580149 bivi:StockOptionOneMember 2018-07-01 2019-03-31 0001580149 bivi:StockOptionOneMember 2019-03-31 0001580149 bivi:StockOptionTwoMember 2018-07-01 2019-03-31 0001580149 bivi:StockOptionTwoMember 2019-03-31 0001580149 bivi:StockOptionThreeMember 2018-07-01 2019-03-31 0001580149 bivi:StockOptionThreeMember 2019-03-31 0001580149 bivi:StockOptionFourMember 2018-07-01 2019-03-31 0001580149 bivi:StockOptionFourMember 2019-03-31 0001580149 bivi:StockOptionFiveMember 2018-07-01 2019-03-31 0001580149 bivi:StockOptionFiveMember 2019-03-31 0001580149 bivi:StockOptionSixMember 2018-07-01 2019-03-31 0001580149 bivi:StockOptionSixMember 2019-03-31 0001580149 bivi:StockOptionSevenMember 2018-07-01 2019-03-31 0001580149 bivi:StockOptionSevenMember 2019-03-31 0001580149 us-gaap:CommonStockMember 2018-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001580149 us-gaap:RetainedEarningsMember 2018-06-30 0001580149 us-gaap:WarrantMember 2018-07-01 2019-03-31 0001580149 us-gaap:StockOptionMember 2018-07-01 2019-03-31 0001580149 us-gaap:StockOptionMember 2018-06-30 0001580149 2019-01-01 2019-03-31 0001580149 2018-01-01 2018-03-31 0001580149 us-gaap:PreferredStockMember 2018-07-01 2018-09-30 0001580149 us-gaap:CommonStockMember 2017-07-01 2017-09-30 0001580149 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001580149 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001580149 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001580149 us-gaap:CommonStockMember 2017-06-30 0001580149 us-gaap:CommonStockMember 2017-12-31 0001580149 us-gaap:CommonStockMember 2018-03-31 0001580149 us-gaap:CommonStockMember 2018-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2017-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001580149 us-gaap:RetainedEarningsMember 2017-07-01 2017-09-30 0001580149 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001580149 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001580149 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001580149 us-gaap:RetainedEarningsMember 2017-06-30 0001580149 us-gaap:RetainedEarningsMember 2017-12-31 0001580149 us-gaap:RetainedEarningsMember 2018-03-31 0001580149 us-gaap:RetainedEarningsMember 2018-12-31 0001580149 2017-07-01 2017-09-30 0001580149 2018-07-01 2018-09-30 0001580149 2017-12-31 0001580149 2018-12-31 0001580149 2017-07-01 2018-06-30 0001580149 bivi:StockOptionEightMember 2019-03-31 0001580149 bivi:StockOptionEightMember 2018-07-01 2019-03-31 0001580149 bivi:StockOptionNineMember 2019-03-31 0001580149 bivi:StockOptionNineMember 2018-07-01 2019-03-31 0001580149 us-gaap:WarrantMember 2018-06-30 0001580149 us-gaap:WarrantMember 2019-03-31 0001580149 2019-03-31 0001580149 us-gaap:CommonStockMember 2017-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001580149 us-gaap:RetainedEarningsMember 2017-09-30 0001580149 2017-09-30 0001580149 us-gaap:CommonStockMember 2017-10-01 2017-12-31 0001580149 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001580149 us-gaap:CommonStockMember 2018-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2017-10-01 2017-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001580149 us-gaap:RetainedEarningsMember 2017-10-01 2017-12-31 0001580149 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001580149 us-gaap:RetainedEarningsMember 2018-09-30 0001580149 2017-10-01 2017-12-31 0001580149 2018-10-01 2018-12-31 0001580149 2018-09-30 0001580149 bivi:StockOptionTenMember 2019-03-31 0001580149 bivi:StockOptionTenMember 2018-07-01 2019-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

1006614

45800

2964272

2175491

179054

884207

179054

1238374

9359780

4870475

2785218

111199

2964272

2175491

10000000

800000000

300000000

316453673

98503199

-1869886

-412061

2795700

435001

31645

9850

0.001

316453673

98503199

-382203

275283

925814

22940

5140

971614

45800

28080

971614

0.0001

354167

187500

-6606207

-4769126

1611947

1783980

345711

1957658

2129691

172033

57344

732373

275116

331834

46420

936180

1401104

459111

587450

1840586

1848253

848289

691215

-1840586

-1848253

-848289

-691215

272

9828

1342

1036

248

-0.01

-0.02

-0.00

-0.01

313580066

95014206

316422562

96939603

7250000

700000

1300000

3100000

100000

500000

200000

550000

5150000

100000

200000

500000

0.10

0.12

445001

49000

242400

150

203

140

329850

242197

48860

330000

34485

34500

316453673 BIOVIE INC. 0001580149 10-Q 2019-03-31 false --06-30 Yes Non-accelerated Filer Q3 2019

825918

51400

179054

2064292

575918

-1788422

-1858080

-848041

-692557

-662841

-692557

-439871

-848041

-662841

-439871

-502682

-500510

-502682

-500510

48659

316453673

98503199

91925000

94971364

97334697

315053673

94594091

315053673

1157318

111199

31645

9359780

-6606207

555442

9850

4870475

-4769126

9193

9498

9734

31505

3483134

4282102

4738797

9267310

-2335009

-3500532

-4193089

-5758166

791068

3540650

2785218

9460

4070619

-2997850

1082229

31505

9251026

-5257656

4024875

48659 -48659

51400

223690548

5150000

4774015

216440548

7250000

9924015

1611947

1783980

1611947

509790

681823

2293770

6250000

700000

1300000

2100000

100000

500000

200000

550000

100000

200000

500000

P4Y9M18D

P4Y7M6D

P6Y10M24D

P4Y6M

P3Y9M18D

P3Y6M

P3Y1M6D

P5Y9M18D

P3Y

P3Y4M24D

P2Y7M6D

P5Y3M18D

4774015

216440548

0.29

0.03

P5Y3M18D

214166533

0.02

P5Y3M18D

P5Y

0.03 0.05 0.06 0.07 0.10 0.20 0.21 0.22 0.23 0.25

3040000

3200000 1150135 98 1150037 1150135 224 224 -224 48659

50000 3200000 117 33 244883 49967 3200000 245000 3200000 23 49977 50000 2133332 1169091 333333 227273 -3200000 21333 -21333 -2133332 213333200

63306

811203

43609

152062

12752

152062

3412

43609

12752

3412

27021

16285

27021

16285

0.10

-1837081

-1858080

-848041

-692557

-52164 9827 -248 1342

250000

57344

229377

637095

true true false

-244300

-10000

1500000

2030000

1400000

150000

100000 100000 975361 2241913

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 11pt/115% Calibri, Helvetica, Sans-Serif">3.</td> <td style="width: 97%; font: 11pt/115% Calibri, Helvetica, Sans-Serif">Significant Accounting Policies</td></tr> </table>   Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018. Net Loss per Common Share Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. The table below shows the number of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: white"> <td style="width: 29%; border: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"> </td> <td style="width: 35%; border-top: white 1pt solid; border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">March 31, 2019</td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="width: 33%; border-top: white 1pt solid; border-right: white 1pt solid; border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">June 30, 2018</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"> </td> <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Number of Shares</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-right: white 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Number of Shares</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Stock Options</td> <td style="border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">7,250,000</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5,150,000</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Warrants</td> <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">216,440,548</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-bottom: Black 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4,774,015</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Total</td> <td style="border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">223,690,548</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-bottom: Black 2.25pt double; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">9,924,015</td></tr> </table>   Recent accounting pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations. In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the financial statements.

4. Intellectual Property Intellectual property, stated at cost, less accumulated amortization consists of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center">March 31, 2019</td> <td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center"> </td> <td style="white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center">June 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Intellectual Property</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      2,293,770 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      2,293,770 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Accumulated Amortization </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            681,823 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            509,790 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Intellectual Property, Net</td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      1,611,947 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      1,783,980 </td></tr> </table>   Amortization expense for the three- and nine-month periods ended March 31, 2019 and 2018 was $57,344 and $172,033, respectively. Estimated future amortization expense is as follows: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Year ending June 2019 (remaining three months)</td> <td style="white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                           57,344 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2020</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            229,377 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2021</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            229,377 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2022</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            229,377 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2023</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            229,377 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Thereafter</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            637,095 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      1,611,947 </td></tr> </table>

5. Renegotiated Debt On July 19, 2018, Geis-Hides Consulting LLC entered into an Accord and Debt Satisfaction Agreement with the Company in which the consulting firm agreed to release the Company from all liabilities arising from the Original Contract and Debt Repayment Plan dated December 15, 2013 totaling $132,000 and received cash of $65,000 and 260,000 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $51,400 on the settlement of debt was reflected on the Statements of Operations as “other income” for the nine-month period ended March 31, 2019.

6. Related Party Transactions On July 9, 2018, Jonathan Adams (COO) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of his accrued salary dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued salary; and subsequent unpaid salary, totaling the amount of $534,722, and received cash of $25,694 in satisfaction. The gain of $509,028 on the settlement of debt was reflected in the additional paid in capital. On July 9, 2018, Elliot Ehrlich (former CEO and shareholder) entered into an Accord and Debt Satisfaction Agreement with the Company in which he agreed to release the Company from all liabilities including the original contract to defer payment of accrued salary dated March 23, 2017, totaling the amount of $222,028 the promissory note issued by the Company to defer payment of accrued salary; and received cash of $22,273 and 222,028 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.06 per common share. The gain of $186,503 on the settlement of debt was reflected in the additional paid in capital. On August 8, 2018, Barrett Ehrlich (Independent contractor, related party to Elliot Ehrlich and shareholder) on behalf of The Barrett Edge Inc. (“Barrett”) entered into an Accord and Debt Satisfaction Agreement with the Company in which Barrett agreed to release the Company from all liabilities including the original contract to defer payment of accrued consulting fees dated March 23, 2017, the promissory note issued by the Company to defer payment of accrued consulting fees; loan to the Company for $14,000, and subsequent unpaid consulting fees, totaling $543,014, and received cash of $131,333 and 493,333 common shares in satisfaction. The common shares were valued at the market price on the date of settlement at $0.13 per common share. The gain of $361,548 on the settlement of debt was reflected in the additional paid in capital. See note 8 for other related party transactions.

7. Commitments and Contingencies  Office Lease  On October 1, 2018, the Company executed a lease agreement with Acuitas Group Holdings, LLC (related party) for the Company’s office at 11601 Wilshire Blvd Ste 1100, Los Angeles, CA 90025. The lease is a month-to-month lease that may be cancelled upon 30 days’ written notice and requires monthly payments of $1,000. Challenge to US Patent On April 30, 2018, the Company received notice that Mallinckrodt Pharmaceuticals Ireland Limited had petitioned the US Patent and Trademark Office (USPTO) to institute an Inter Partes Review of BioVie’s US Patent No. 9,655,945 titled “Treatment of Ascites” (the ‘945 patent). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications. On August 15, 2018, BioVie submitted a Preliminary Response to the PTAB providing a rationale as to why, in the Company’s opinion, Mallinckrodt’s request to institute the IPR should not be granted. On November 14, 2018, the PTAB granted institution of the IPR challenge after determining that there was a reasonable likelihood of success in proving that at least one of the Company’s 14 claims was unpatentable. On March 7, 2019, we submitted a Patent Owner’s Response and a Patent Owner’s Contingent-Motion to Amend our patent claims, and Declaration of Dr. Jaime Bosch, MD, PhD, our medical expert. We are actively defending the ‘945 patent and may explore the possibility of settlement with Mallinckrodt. However, there can be no assurance in that a favorable outcome will result, or if settlement is reached that the PTAB will accept it. Although the PTAB encourages settlement, in view of public-interest considerations, the board may continue the proceeding to a final written decision even if the parties settle. If the IPR is not terminated due to settlement, the PTAB is statutorily required to issue its final written decision in this case before November 14, 2019. As of March 31, 2019, no adjustments or accruals are reflected as the Company is unable to determine a likely outcome at this time. Royalty Agreements Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation; and The Barrett Edge, Inc. The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged. Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.

8. Equity Transactions Stock Options The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td rowspan="5" style="vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Options</td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td rowspan="5" style="vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted-Average Exercise Price</td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td rowspan="5" style="vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted Remaining Average Contractual Term</td> <td style="white-space: nowrap; vertical-align: bottom; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td rowspan="5" style="vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Aggregate Intrinsic Value</td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Outstanding at June 30, 2018</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">5,150,000 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                 0.12 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5.8 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                     -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Granted </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">2,100,000 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                 0.04 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4.6 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $             88,370 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Options Exercised or Forfeited</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">                        -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                     -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">-</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                     -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Outstanding at March 31, 2019</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">7,250,000 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                 0.10 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5.3 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $           166,175 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Exercisable at March 31, 2019</td> <td style="white-space: nowrap; border-top: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">6,250,000 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                 0.10 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5.3 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                     -   </td></tr> </table>   The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option – Pricing model reflecting the following weighted-average assumptions: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">March 31,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 62%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; width: 18%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2019</td> <td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 18%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Expected life of options (In years)</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Expected volatility</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">69.77%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">69.66%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Risk free interest rate</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2.60%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">1.59%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Dividend Yield</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">0%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">0%</td></tr> </table>   Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred. The Company recorded stock-based compensation expense of $43,609 and $63,306 for the three-and nine-month periods ended March 31, 2019, respectively, and $152,062 and $191,835 for the three-and nine-month periods ended March 31, 2018, respectively. The fair value of options vested during the nine-month period ended March 31, 2019 and 2018, was $10,235 and $25,281 respectively. As of March 31, 2019, there was approximately $1,555 of unrecognized compensation cost related to non-vested options granted which is expected to be recognized over a weighted-average period of 1 months. The following is a summary of stock options outstanding and exercisable by exercise price as of March 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td rowspan="4" style="width: 23%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted Average Contract Life</td> <td style="white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Exercise Price</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Outstanding</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Exercisable</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.03 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">700,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4.8</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">700,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.05 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">1,300,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4.6</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">1,300,000</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; background-color: white; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.06 </td> <td style="white-space: nowrap; background-color: white; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3,100,000</td> <td style="white-space: nowrap; background-color: white; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">6.9</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2,100,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.07 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">100,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4.5</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">100,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.10 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">500,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.8</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">500,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.20 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">200,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.5</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">200,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.21 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">550,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.1</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">550,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.22 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">100,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.0</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">100,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.23 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">200,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.4</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">200,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.25 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">500,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2.6</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">500,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Total</td> <td style="white-space: nowrap; border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">7,250,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">6,250,000</td></tr> </table>   Offerings of Common Stock and Warrants Issuance of Shares for Cash On July 3, 2018, BioVie Inc., the Company, entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holdings, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the Company’s newly created Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) the Company will issue associated warrants (the “Warrants”) to purchase 213,333,200 shares of the Company’s Class A Common Stock (the “Common Stock”), each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. The Company received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued by the Company in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas has the option to purchase up to an additional 200,000,000 shares of Common Stock at a price per share of $0.015, and associated warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that the Company has not obtained $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale. Each share of Preferred Stock automatically converted into 100 shares of Common Stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to the Company’s Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of Common Stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of the Company’s issued and outstanding Common Stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of the Company’s Definitive Information that was filed with the Securities and Exchange Commission. The purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants, and the Common Stock in the Subsequent Sale is subject to adjustment. In the event that Mallinckrodt Pharmaceuticals Ireland Limited prevails in any proceeding which results in the useful life of the Company’s current intellectual property rights being reduced by more than 75 percent, then the price per share of Common Stock, the associated conversion ratio of the Preferred Stock, and the exercise price of the Warrants shall be retroactively adjusted to 50 percent of the then-effective price per share of Common Stock under the Purchase Agreement (for example, if the then-effective price per share of Common Stock is $0.015, then following such event, the price per share will be $0.0075). In this case, the Company may be required to issue additional shares of Common Stock, but in no event will the Company be required to pay cash, to reflect such lower price per share. The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, the Company also disclosed customary information, including the following: (i) the existence of the Mallinckrodt Pharmaceuticals Ireland Limited petition before the US Patent Trial and Appeal Board, (ii) the current capitalization of the Company, (iii) the Company’s obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and the Company, (iv) the Company’s obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between the Company and the University of Padova (Italy), and (v) certain recent issuances of Common Stock by the Company. Pursuant to the Purchase Agreement, Terren Peizer, the Chairman of Acuitas, was appointed as a member of the Company’s Board of Directors (the “Board”) and as the Chief Executive Officer of the Company, effective July 3, 2018. The issuance of the Preferred Stock, the Warrants and the underlying common stock under the Purchase Agreement is exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act. Issuance of Shares for Services On January 2, 2019, the Company issued 1,400,000 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $0.035 per share.   Issuance of Shares in Settlement of Debt During the nine months ended March 31, 2019, the Company settled $1,475,765 of debt including $1,313,765 owed to related parties, by issuing 975,361 shares of common stock with a fair value of $1,150,135. See notes 5 and 6. Issuance of Stock Options On October 1, 2018, the Company issued stock options to purchase 100,000 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $0.07 at any time from date of issuance and expire in 5 years from the date of issuance. On October 13, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance. On October 27, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance On November 10, 2018, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options are exercisable at an exercise price of $0.05 at any time from date of issuance and expire in 5 years from the date of issuance. On January 19, 2019, the Company issued stock options to purchase 100,000 shares of common stock to each of five key employees or consultants and two company directors as part of his or her annual compensation, for an aggregate total of 700,000 stock options. The stock options are exercisable at an exercise price of $0.025 at any time from date of issuance until 5 years from the date of issuance. On March 11, 2019, the Company issued stock options to purchase 1,000,000 shares of common stock to an investor relations (IR) consultant. The stock options were issued and are exercisable at $0.05 at any time from date of issuance and expire in 5 years from the date of issuance. Cashless exercise of warrant On August 4, 2018, the Company issued 2,241,913 shares of common stock pursuant to a cash less exercise of warrants to purchase 2,500,000 shares at an exercise price of $0.015 per share. As a result of the conversion of the Series A Preferred Stock in July 2018, the exercise of warrants to purchase 2,500,000 shares of common stock was reduced from $0.15 per share to $0.015 per share.   Warrant Price Adjustment In December 2017, the Company issued warrants to purchase 2,500,000 shares of common stock in a private placement transaction for aggregate gross proceeds of $100,000. The warrants were exercisable at an exercise price of $0.20 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In January 2018, the Company sold shares at $0.15, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $20,995 as a deemed dividend. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $44,889 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method. In January 2018, the Company issued warrants to purchase 210,000 shares of common stock in exchange for banking services which was recognized at fair value. The warrants were exercisable at an exercise price of $0.15 at any time from date of issuance until 7 years from the date of issuance. The warrants have a down round feature that reduces the exercise price if the Company sells stock for a lower price. In July 2018, the Company sold shares at $0.015, which therefore triggered the reduction in the strike price. The Company calculated the difference in fair value of the warrants between the stated exercise price and the reduced exercise price and recorded $3,770 as a deemed dividend. The fair value of the warrants granted was estimated using the Black Scholes Method. The following table summarizes the warrants that have been issued: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted Average </td> <td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted Average </td> <td style="white-space: nowrap; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Agggregate</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Number of Shares</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Exercise Price</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Remaining Life (Years)</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Outstanding at June 30, 2018</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4,774,015</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                                            0.29 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">                                                 5.5 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                           -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Granted</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">214,166,533</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                                            0.02 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">                                                 5.3 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $            14,284,908 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Expired</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">-</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                                               -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">                                                  -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                           -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Exercised</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">(2,500,000)</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                                            0.02 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">                                                  -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%"> $                           -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Outstanding and exercisable at March 31, 2019</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">216,440,548</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                                            0.03 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">                                                 5.3 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $            14,284,908 </td></tr> </table>   Of the above warrants, 1,173,864 expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 214,709,866 expire in fiscal year ending June 30, 2025.

Basis of Presentation – Interim Financial Information The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The Condensed Balance Sheet at June 30, 2018 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2018 filed with the SEC on October 5, 2018. For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018.

Net Loss per Common Share Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive. The table below shows the number of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: white"> <td style="width: 29%; border: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"> </td> <td style="width: 35%; border-top: white 1pt solid; border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">March 31, 2019</td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="width: 33%; border-top: white 1pt solid; border-right: white 1pt solid; border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">June 30, 2018</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"> </td> <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Number of Shares</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-right: white 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Number of Shares</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Stock Options</td> <td style="border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">7,250,000</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5,150,000</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Warrants</td> <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">216,440,548</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-bottom: Black 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4,774,015</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Total</td> <td style="border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">223,690,548</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-bottom: Black 2.25pt double; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">9,924,015</td></tr> </table>

Recent accounting pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations. In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of this ASU on the financial statements.

The table below shows the number of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: white"> <td style="width: 29%; border: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"> </td> <td style="width: 35%; border-top: white 1pt solid; border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">March 31, 2019</td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="width: 33%; border-top: white 1pt solid; border-right: white 1pt solid; border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">June 30, 2018</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; line-height: 115%"> </td> <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Number of Shares</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-right: white 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Number of Shares</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Stock Options</td> <td style="border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">7,250,000</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-bottom: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5,150,000</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Warrants</td> <td style="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">216,440,548</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-bottom: Black 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4,774,015</td></tr> <tr style="background-color: white"> <td style="border-right: white 1pt solid; border-bottom: white 1pt solid; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Total</td> <td style="border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">223,690,548</td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="border-bottom: Black 2.25pt double; border-left: white 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">9,924,015</td></tr> </table>

Intellectual property, stated at cost, less accumulated amortization consists of the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center">March 31, 2019</td> <td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center"> </td> <td style="white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center">June 30, 2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Intellectual Property</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      2,293,770 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      2,293,770 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Accumulated Amortization </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            681,823 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            509,790 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Intellectual Property, Net</td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      1,611,947 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      1,783,980 </td></tr> </table>

Estimated future amortization expense is as follows: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 68%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Year ending June 2019 (remaining three months)</td> <td style="white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                           57,344 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2020</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            229,377 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2021</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            229,377 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2022</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            229,377 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2023</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            229,377 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Thereafter</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">                            637,095 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                      1,611,947 </td></tr> </table>

The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; width: 43%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td rowspan="5" style="vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Options</td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td rowspan="5" style="vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted-Average Exercise Price</td> <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td rowspan="5" style="vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted Remaining Average Contractual Term</td> <td style="white-space: nowrap; vertical-align: bottom; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td rowspan="5" style="vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Aggregate Intrinsic Value</td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td></tr> <tr style="background-color: white"> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; vertical-align: bottom; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Outstanding at June 30, 2018</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">5,150,000 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                 0.12 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5.8 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                     -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Granted </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">2,100,000 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                 0.04 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4.6 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $             88,370 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Options Exercised or Forfeited</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">                        -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                     -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">-</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                     -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Outstanding at March 31, 2019</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">7,250,000 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                 0.10 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5.3 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $           166,175 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Exercisable at March 31, 2019</td> <td style="white-space: nowrap; border-top: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">6,250,000 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                 0.10 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5.3 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 2.25pt double; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                     -   </td></tr> </table>   The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option – Pricing model reflecting the following weighted-average assumptions: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">March 31,</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 62%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; width: 18%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2019</td> <td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 18%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2018</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Expected life of options (In years)</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">5</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Expected volatility</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">69.77%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">69.66%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Risk free interest rate</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2.60%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">1.59%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Dividend Yield</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">0%</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">0%</td></tr> </table>

The following is a summary of stock options outstanding and exercisable by exercise price as of March 31, 2019: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 29%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td rowspan="4" style="width: 23%; border-bottom: black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted Average Contract Life</td> <td style="white-space: nowrap; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Exercise Price</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Outstanding</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Exercisable</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.03 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">700,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4.8</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">700,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.05 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">1,300,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4.6</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">1,300,000</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; background-color: white; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.06 </td> <td style="white-space: nowrap; background-color: white; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3,100,000</td> <td style="white-space: nowrap; background-color: white; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">6.9</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2,100,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.07 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">100,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4.5</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">100,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.10 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">500,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.8</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">500,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.20 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">200,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.5</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">200,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.21 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">550,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.1</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">550,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.22 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">100,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.0</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">100,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.23 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">200,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">3.4</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">200,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                       0.25 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">500,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">2.6</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">500,000</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Total</td> <td style="white-space: nowrap; border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">7,250,000</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-top: Black 1pt solid; border-bottom: Black 2.25pt double; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">6,250,000</td></tr> </table>

The following table summarizes the warrants that have been issued: <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; width: 16%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted Average </td> <td style="white-space: nowrap; width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; width: 17%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Weighted Average </td> <td style="white-space: nowrap; width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; width: 10%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Agggregate</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Number of Shares</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Exercise Price</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Remaining Life (Years)</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Outstanding at June 30, 2018</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">4,774,015</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                                            0.29 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">                                                 5.5 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                           -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Granted</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">214,166,533</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                                            0.02 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">                                                 5.3 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $            14,284,908 </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Expired</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">-</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                                               -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">                                                  -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $                           -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Exercised</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">(2,500,000)</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                                            0.02 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%">                                                  -   </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; line-height: 115%"> $                           -   </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%">Outstanding and exercisable at March 31, 2019</td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">216,440,548</td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> $                                            0.03 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%">                                                 5.3 </td> <td style="white-space: nowrap; padding-right: 5.4pt; padding-left: 5.4pt; line-height: 115%"> </td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; line-height: 115%"> $            14,284,908 </td></tr> </table>

2100000

0.04

P4Y7M6D

-2500000

0.02

166175

14284908

88370

35000

-35000

12469

9. Subsequent Events In April 2019, to facilitate the Company’s planned uplisting to the NASDAQ Stock Market and related potential future issuances and sales of equity securities for ordinary corporate finance and general corporate purposes and as recommended by the Board of Directors (“Board”), the Company’s stockholders approved an amendment to the Company’s Articles of Incorporation to effect a reverse split of its outstanding Class A common stock in the range of 50:1 to 200:1, as determined by the Board. Following that approval, the Company filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the “S-1 Registration Statement”) pursuant to which it anticipates completing an offering of equity securities with proceeds sufficient to enable the launch and completion of the BIV201 Phase 2b study and fund internal operations for at least the next twelve months.

EX-101.CAL 7 bivi-20190331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bivi-20190331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bivi-20190331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Capital in Excess of Par Value Accumulated Deficit Derivative Instrument [Axis] Stock Option [Member] Warrant [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Additional Paid-In Capital Preferred Stock Stock Option [Member] Stock Option [Member] Stock Option [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Shell Company Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Other Assets Total Current Assets OTHER ASSETS: Intangible Assets Goodwill Total Fixed Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts Payable and accrued expenses Accrued Payroll Total Current Liabilities LONG TERM LIABILITIES: Demand Promissory Note Notes Payable, Related Parties Total Long Term Liabilities TOTAL LIABILITIES Commitments and contingencies STOCKHOLDERS' EQUITY Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding Common stock, $0.0001 par value; 800,000,000 and 300,000,000 shares authorized at March 31, 2019 and June 30, 2018, respectively; 316,453,673 and 98,503,199 shares issued and outstanding at March 31, 2019 and June 30, 2018, respectively Additional paid in capital Accumulated deficit Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common Stock Shares Issued Common stock, shares outstanding Income Statement [Abstract] REVENUE OPERATING EXPENSES Amortization Research and development expenses Selling, general and administrative expenses TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER EXPENSE (INCOME) Other Income Interest Expense Interest income TOTAL OTHER EXPENSE (INCOME) NET LOSS Deemed dividend NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS NET LOSS PER COMMON SHARE, BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash to cash used by operating activities: Common shares issued for service Amortization of intangible assets Stock based compensation expense Gain on settlement of debt Changes in operating assets and liabilities: Other assets Accounts Payable Accrued Payroll Net cash used by operating activities CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of debt Proceeds from issuance of preferred shares Proceeds from issuance of common stock and warrants Net cash provided by financing activities Net decrease in cash Cash, beginning of period Cash, end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Cash paid for taxes NON-CASH INVESTING AND FINANCING ACTIVITIES Conversion of preferred shares to common stock Settlement of debt by issuance of common stock Cashless exercise of warrants Deemed dividends for ratchet adjustments to warrants Statement [Table] Statement [Line Items] Beginning Balance Beginning Balance, Shares Issuance of shares in a private placement Issuance of shares in a private placement (in shares) Issuance of shares for services Issuance of shares for services, Shares Conversion of preferred stock to common stock Conversion of preferred stock to common stock (in shares) Issuance of shares in exchange for debt settlement Issuance of shares in exchange for debt settlement, Shares Issuance of warrants in a private placement Issuance of warrants for services Stock option compensation Cashless exercise of warrants, Shares Deemed dividends for ratchet adjustment to warrants Ending Balance Ending Balance, Shares Notes to Financial Statements Background Information Liquidity Accounting Policies [Abstract] Significant Accounting Policies Related Party Transactions [Abstract] Intellectual Property Renegotiated Debt Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Equity Transactions Subsequent Events [Abstract] Subsequent Events Basis of Presentation Net Loss per Common Share Recent accounting pronouncements Significant Accounting Policies Schedule of Dilutive securities were excluded from the computation of diluted loss per share Intellectual Property Schedule of Intangible Assets Schedule of Future expected Amortization of intangible assets Equity Transactions Schedule of Stock Option Issued Schedule of option outstanding and exercisable by exercise price Schedule of Warrants Issued Dilutive Securities excluded from the Computation of Diluted Loss Per Share Intellectual Property Intellectual Property Accumulated Amortization Intellectual Property, Net Intellectual Property 2019 2020 2021 2022 2023 Thereafter Option Outstanding at beginning of period Option Granted Option Exercised Option Forfeited Option Outstanding at end of period Option Excersiable at end of period Outstanding Weighted Average Exercise Price at the beginning of period Weighted Average Exercise Price, Granted Weighted Average Exercise Price, Exercised Weighted Average Exercise Price, Forfeited Outstanding Weighted Average Exercise Price at the end of period Excersiable Weighted Average Exercise Price at the end of period Weighted Average Remaining Contractual Term at the beginning of period Weighted Average Remaining Contractual Term, Granted Weighted Average Remaining Contractual Term, Excerised Weighted Average Remaining Contractual Term at the end Excersiable Weighted Average Remaining Contractual Term at the end of period Aggregate Intrinsic Value Outstanding at beginning of period EX-101.PRE 10 bivi-20190331_pre.xml XBRL PRESENTATION FILE EX-101.SCH 11 bivi-20190331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Background Information link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intellectual Property link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Renegotiated Note link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Intellectual Property (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Intellectual Property (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intellectual Property (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Equity Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Equity Transactions (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Equity Transactions (Details 3) link:presentationLink link:calculationLink link:definitionLink XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	May 10, 2019
Document And Entity Information
Entity Registrant Name	BIOVIE INC.
Entity Central Index Key	0001580149
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		316,453,673
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheet (Unaudited) - USD ($)	May 10, 2019	Jun. 30, 2018
CURRENT ASSETS:
Cash	$ 971,614	$ 45,800
Other Assets	35,000
Total Current Assets	1,006,614	45,800
OTHER ASSETS:
Intangible Assets	1,611,947	1,783,980
Goodwill	345,711	345,711
Total Fixed Assets	1,957,658	2,129,691
TOTAL ASSETS	2,964,272	2,175,491
CURRENT LIABILITIES:
Accounts Payable and accrued expenses	179,054	884,207
Accrued Payroll		354,167
Total Current Liabilities	179,054	1,238,374
LONG TERM LIABILITIES:
Demand Promissory Note		250,000
Notes Payable, Related Parties		575,918
Total Long Term Liabilities		825,918
TOTAL LIABILITIES	179,054	2,064,292
Commitments and contingencies
STOCKHOLDERS' EQUITY
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 and 300,000,000 shares authorized at March 31, 2019 and June 30, 2018, respectively; 316,453,673 and 98,503,199 shares issued and outstanding at March 31, 2019 and June 30, 2018, respectively	31,645	9,850
Additional paid in capital	9,359,780	4,870,475
Accumulated deficit	(6,606,207)	(4,769,126)
Total Stockholders' Equity	2,785,218	111,199
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,964,272	$ 2,175,491

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheet (Unaudited) (Parenthetical) - $ / shares	May 10, 2019	Jun. 30, 2018
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	800,000,000	300,000,000
Common Stock Shares Issued	316,453,673	98,503,199
Common stock, shares outstanding	316,453,673	98,503,199

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
REVENUE
OPERATING EXPENSES
Amortization	57,344	57,344	172,033	172,033
Research and development expenses	331,834	46,420	732,373	275,116
Selling, general and administrative expenses	459,111	587,450	936,180	1,401,104
TOTAL OPERATING EXPENSES	848,289	691,215	1,840,586	1,848,253
LOSS FROM OPERATIONS	(848,289)	(691,215)	(1,840,586)	(1,848,253)
OTHER EXPENSE (INCOME)
Other Income			(51,400)
Interest Expense		1,342	272	9,828
Interest income	(248)		(1,036)	(1)
TOTAL OTHER EXPENSE (INCOME)	(248)	1,342	(52,164)	9,827
NET LOSS	(848,041)	(692,557)	(1,788,422)	(1,858,080)
Deemed dividend			48,659
NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS	$ (848,041)	$ (692,557)	$ (1,837,081)	$ (1,858,080)
NET LOSS PER COMMON SHARE, BASIC AND DILUTED	$ (0.00)	$ (0.01)	$ (0.01)	$ (0.02)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED	316,422,562	96,939,603	313,580,066	95,014,206

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,788,422)	$ (1,858,080)
Adjustments to reconcile net loss to net cash to cash used by operating activities:
Common shares issued for service	49,000
Amortization of intangible assets	172,033	172,033
Stock based compensation expense	63,306	811,203
Gain on settlement of debt	51,400
Changes in operating assets and liabilities:
Other assets	(35,000)
Accounts Payable	(382,203)	275,283
Accrued Payroll		187,500
Net cash used by operating activities	(1,869,886)	(412,061)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt	(244,300)	(10,000)
Proceeds from issuance of preferred shares	3,040,000
Proceeds from issuance of common stock and warrants		445,001
Net cash provided by financing activities	2,795,700	435,001
Net decrease in cash	925,814	22,940
Cash, beginning of period	45,800	5,140
Cash, end of period	971,614	28,080
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest
Cash paid for taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES
Conversion of preferred shares to common stock	3,200,000
Settlement of debt by issuance of common stock	1,150,135
Cashless exercise of warrants	224
Deemed dividends for ratchet adjustments to warrants	$ 48,659

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance at Jun. 30, 2017		$ 9,193	$ 3,483,134	$ (2,335,009)	$ 1,157,318
Beginning Balance, Shares at Jun. 30, 2017		91,925,000
Issuance of shares in a private placement		$ 117	244,883		245,000
Issuance of shares in a private placement (in shares)		1,169,091
Issuance of shares for services		$ 150	329,850		330,000
Issuance of shares for services, Shares		1,500,000
Stock option compensation			12,752		12,752
Net loss				(662,841)	(662,841)
Ending Balance at Sep. 30, 2017		$ 9,460	4,070,619	(2,997,850)	1,082,229
Ending Balance, Shares at Sep. 30, 2017		94,594,091
Beginning Balance at Jun. 30, 2017		$ 9,193	3,483,134	(2,335,009)	1,157,318
Beginning Balance, Shares at Jun. 30, 2017		91,925,000
Issuance of shares for services
Issuance of shares in exchange for debt settlement
Stock option compensation					811,203
Cashless exercise of warrants
Net loss					(1,858,080)
Ending Balance at Mar. 31, 2018		$ 9,734	4,738,797	(4,193,089)	555,442
Ending Balance, Shares at Mar. 31, 2018		97,334,697
Beginning Balance at Sep. 30, 2017		$ 9,460	4,070,619	(2,997,850)	1,082,229
Beginning Balance, Shares at Sep. 30, 2017		94,594,091
Issuance of shares in a private placement		$ 23	49,977		50,000
Issuance of shares in a private placement (in shares)		227,273
Issuance of shares for services		$ 15	34,485		34,500
Issuance of shares for services, Shares		150,000
Issuance of warrants in a private placement			100,000		100,000
Stock option compensation			27,021		27,021
Net loss				(502,682)	(502,682)
Ending Balance at Dec. 31, 2017		$ 9,498	4,282,102	(3,500,532)	791,068
Ending Balance, Shares at Dec. 31, 2017		94,971,364
Issuance of shares in a private placement		$ 33	49,967		50,000
Issuance of shares in a private placement (in shares)		333,333
Issuance of shares for services		$ 203	242,197		242,400
Issuance of shares for services, Shares		2,030,000
Issuance of warrants for services			12,469		12,469
Stock option compensation			152,062		152,062
Net loss				(692,557)	(692,557)
Ending Balance at Mar. 31, 2018		$ 9,734	4,738,797	(4,193,089)	555,442
Ending Balance, Shares at Mar. 31, 2018		97,334,697
Beginning Balance at Jun. 30, 2018		$ 9,850	4,870,475	(4,769,126)	111,199
Beginning Balance, Shares at Jun. 30, 2018		98,503,199
Issuance of shares in a private placement	$ 3,200,000		3,200,000		3,200,000
Issuance of shares in a private placement (in shares)	2,133,332
Conversion of preferred stock to common stock	$ (3,200,000)	$ 21,333	(21,333)
Conversion of preferred stock to common stock (in shares)	(2,133,332)	213,333,200
Issuance of shares in exchange for debt settlement		$ 98	1,150,037		1,150,135
Issuance of shares in exchange for debt settlement, Shares		975,361
Stock option compensation			3,412		3,412
Cashless exercise of warrants		$ 224	(224)
Cashless exercise of warrants, Shares		2,241,913
Deemed dividends for ratchet adjustment to warrants			48,659	(48,659)
Net loss				(439,871)	(439,871)
Ending Balance at Sep. 30, 2018		$ 31,505	9,251,026	(5,257,656)	4,024,875
Ending Balance, Shares at Sep. 30, 2018		315,053,673
Beginning Balance at Jun. 30, 2018		$ 9,850	4,870,475	(4,769,126)	111,199
Beginning Balance, Shares at Jun. 30, 2018		98,503,199
Issuance of shares for services					49,000
Issuance of shares in exchange for debt settlement					1,150,135
Stock option compensation					63,306
Cashless exercise of warrants					224
Net loss					(1,788,422)
Ending Balance at Mar. 31, 2019		$ 31,645	9,359,780	(6,606,207)	2,785,218
Ending Balance, Shares at Mar. 31, 2019		316,453,673
Beginning Balance at Sep. 30, 2018		$ 31,505	9,251,026	(5,257,656)	4,024,875
Beginning Balance, Shares at Sep. 30, 2018		315,053,673
Stock option compensation			16,285		16,285
Net loss				(500,510)	(500,510)
Ending Balance at Dec. 31, 2018		$ 31,505	9,267,310	(5,758,166)	3,540,650
Ending Balance, Shares at Dec. 31, 2018		315,053,673
Issuance of shares for services		$ 140	48,860		49,000
Issuance of shares for services, Shares		1,400,000
Stock option compensation			43,609		43,609
Net loss				(848,041)	(848,041)
Ending Balance at Mar. 31, 2019		$ 31,645	$ 9,359,780	$ (6,606,207)	$ 2,785,218
Ending Balance, Shares at Mar. 31, 2019		316,453,673

XML 18 R7.htm IDEA: XBRL DOCUMENT

Background Information

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Background Information

1.	Background Information

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company’s business plan.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Liquidity

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Liquidity

2.	Liquidity and Going Concern

XML 20 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Significant Accounting Policies

3.	Significant Accounting Policies

Basis of Presentation – Interim Financial Information

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018.

Net Loss per Common Share

The table below shows the number of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:

	March 31, 2019	June 30, 2018
	Number of Shares	Number of Shares
Stock Options	7,250,000	5,150,000
Warrants	216,440,548	4,774,015
Total	223,690,548	9,924,015

Recent accounting pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

Intellectual Property

9 Months Ended

Mar. 31, 2019

Intellectual Property

4. Intellectual Property

Intellectual property, stated at cost, less accumulated amortization consists of the following:

	March 31, 2019	June 30, 2018

Intellectual Property	$ 2,293,770	$ 2,293,770
Accumulated Amortization	681,823	509,790
Intellectual Property, Net	$ 1,611,947	$ 1,783,980

Amortization expense for the three- and nine-month periods ended March 31, 2019 and 2018 was $57,344 and $172,033, respectively. Estimated future amortization expense is as follows:

Year ending June 2019 (remaining three months)	$ 57,344
2020	229,377
2021	229,377
2022	229,377
2023	229,377
Thereafter	637,095
	$ 1,611,947

XML 22 R11.htm IDEA: XBRL DOCUMENT

Renegotiated Note

9 Months Ended

Mar. 31, 2019

Notes to Financial Statements

Renegotiated Debt

5. Renegotiated Debt

XML 23 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Mar. 31, 2019

Related Party Transactions

6. Related Party Transactions

See note 8 for other related party transactions.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Mar. 31, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

7. Commitments and Contingencies

Office Lease

Challenge to US Patent

Royalty Agreements

XML 25 R14.htm IDEA: XBRL DOCUMENT

Equity Transactions

9 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Equity Transactions

8. Equity Transactions

Stock Options

The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2019:

	Options	Weighted-Average Exercise Price	Weighted Remaining Average Contractual Term	Aggregate Intrinsic Value




Outstanding at June 30, 2018	5,150,000	$ 0.12	5.8	$ -
Granted	2,100,000	$ 0.04	4.6	$ 88,370
Options Exercised or Forfeited	-	$ -	-	$ -
Outstanding at March 31, 2019	7,250,000	$ 0.10	5.3	$ 166,175
Exercisable at March 31, 2019	6,250,000	$ 0.10	5.3	$ -

The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option – Pricing model reflecting the following weighted-average assumptions:

	March 31,
	2019	2018
Expected life of options (In years)	5	5
Expected volatility	69.77%	69.66%
Risk free interest rate	2.60%	1.59%
Dividend Yield	0%	0%

The fair value of options vested during the nine-month period ended March 31, 2019 and 2018, was $10,235 and $25,281 respectively.

The following is a summary of stock options outstanding and exercisable by exercise price as of March 31, 2019:

		Weighted Average Contract Life


Exercise Price	Outstanding		Exercisable
$ 0.03	700,000	4.8	700,000
$ 0.05	1,300,000	4.6	1,300,000
$ 0.06	3,100,000	6.9	2,100,000
$ 0.07	100,000	4.5	100,000
$ 0.10	500,000	3.8	500,000
$ 0.20	200,000	3.5	200,000
$ 0.21	550,000	3.1	550,000
$ 0.22	100,000	3.0	100,000
$ 0.23	200,000	3.4	200,000
$ 0.25	500,000	2.6	500,000
Total	7,250,000		6,250,000

Offerings of Common Stock and Warrants

Issuance of Shares for Cash

Issuance of Shares for Services

On January 2, 2019, the Company issued 1,400,000 shares of common stock as part of the annual board of director compensation. The share price on date of issuance was $0.035 per share.

Issuance of Shares in Settlement of Debt

Issuance of Stock Options

Cashless exercise of warrant

Warrant Price Adjustment

The following table summarizes the warrants that have been issued:

		Weighted Average	Weighted Average	Agggregate
	Number of Shares	Exercise Price	Remaining Life (Years)	Intrinsic Value
Outstanding at June 30, 2018	4,774,015	$ 0.29	5.5	$ -
Granted	214,166,533	$ 0.02	5.3	$ 14,284,908
Expired	-	$ -	-	$ -
Exercised	(2,500,000)	$ 0.02	-	$ -
Outstanding and exercisable at March 31, 2019	216,440,548	$ 0.03	5.3	$ 14,284,908

Of the above warrants, 1,173,864 expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 214,709,866 expire in fiscal year ending June 30, 2025.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Mar. 31, 2019

Subsequent Events [Abstract]

Subsequent Events

9. Subsequent Events

XML 27 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation – Interim Financial Information

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2018 filed with the SEC on October 5, 2018.

Net Loss per Common Share

Net Loss per Common Share

The table below shows the number of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:

	March 31, 2019	June 30, 2018
	Number of Shares	Number of Shares
Stock Options	7,250,000	5,150,000
Warrants	216,440,548	4,774,015
Total	223,690,548	9,924,015

Recent accounting pronouncements

Recent accounting pronouncements

XML 28 R17.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

9 Months Ended

Mar. 31, 2019

Disclosure Significant Accounting Policies Tables Abstract

Schedule of Dilutive securities were excluded from the computation of diluted loss per share

The table below shows the number of outstanding stock options and warrants as of March 31, 2019 and June 30, 2018:

	March 31, 2019	June 30, 2018
	Number of Shares	Number of Shares
Stock Options	7,250,000	5,150,000
Warrants	216,440,548	4,774,015
Total	223,690,548	9,924,015

XML 29 R18.htm IDEA: XBRL DOCUMENT

Intellectual Property (Tables)

9 Months Ended

Mar. 31, 2019

Disclosure Intangible Assets Tables Abstract

Schedule of Intangible Assets

Intellectual property, stated at cost, less accumulated amortization consists of the following:

	March 31, 2019	June 30, 2018

Intellectual Property	$ 2,293,770	$ 2,293,770
Accumulated Amortization	681,823	509,790
Intellectual Property, Net	$ 1,611,947	$ 1,783,980

Schedule of Future expected Amortization of intangible assets

Estimated future amortization expense is as follows:

Year ending June 2019 (remaining three months)	$ 57,344
2020	229,377
2021	229,377
2022	229,377
2023	229,377
Thereafter	637,095
	$ 1,611,947

XML 30 R19.htm IDEA: XBRL DOCUMENT

Equity Transactions (Tables)

9 Months Ended

Mar. 31, 2019

Disclosure Stock Options Tables Abstract

Schedule of Stock Option Issued

The following table summarizes the activity relating to the Company’s stock options for the nine months ended March 31, 2019:

	Options	Weighted-Average Exercise Price	Weighted Remaining Average Contractual Term	Aggregate Intrinsic Value




Outstanding at June 30, 2018	5,150,000	$ 0.12	5.8	$ -
Granted	2,100,000	$ 0.04	4.6	$ 88,370
Options Exercised or Forfeited	-	$ -	-	$ -
Outstanding at March 31, 2019	7,250,000	$ 0.10	5.3	$ 166,175
Exercisable at March 31, 2019	6,250,000	$ 0.10	5.3	$ -

The fair value of each option grant on the date of grant is estimated using the Black-Scholes Option – Pricing model reflecting the following weighted-average assumptions:

	March 31,
	2019	2018
Expected life of options (In years)	5	5
Expected volatility	69.77%	69.66%
Risk free interest rate	2.60%	1.59%
Dividend Yield	0%	0%

Schedule of option outstanding and exercisable by exercise price

The following is a summary of stock options outstanding and exercisable by exercise price as of March 31, 2019:

		Weighted Average Contract Life


Exercise Price	Outstanding		Exercisable
$ 0.03	700,000	4.8	700,000
$ 0.05	1,300,000	4.6	1,300,000
$ 0.06	3,100,000	6.9	2,100,000
$ 0.07	100,000	4.5	100,000
$ 0.10	500,000	3.8	500,000
$ 0.20	200,000	3.5	200,000
$ 0.21	550,000	3.1	550,000
$ 0.22	100,000	3.0	100,000
$ 0.23	200,000	3.4	200,000
$ 0.25	500,000	2.6	500,000
Total	7,250,000		6,250,000

Schedule of Warrants Issued

The following table summarizes the warrants that have been issued:

		Weighted Average	Weighted Average	Agggregate
	Number of Shares	Exercise Price	Remaining Life (Years)	Intrinsic Value
Outstanding at June 30, 2018	4,774,015	$ 0.29	5.5	$ -
Granted	214,166,533	$ 0.02	5.3	$ 14,284,908
Expired	-	$ -	-	$ -
Exercised	(2,500,000)	$ 0.02	-	$ -
Outstanding and exercisable at March 31, 2019	216,440,548	$ 0.03	5.3	$ 14,284,908

XML 31 R20.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details) - shares	9 Months Ended	12 Months Ended
Significant Accounting Policies (Details) - shares	Mar. 31, 2019	Jun. 30, 2018
Dilutive Securities excluded from the Computation of Diluted Loss Per Share	223,690,548	9,924,015
Warrant [Member]
Dilutive Securities excluded from the Computation of Diluted Loss Per Share	216,440,548	4,774,015
Stock Option [Member]
Dilutive Securities excluded from the Computation of Diluted Loss Per Share	7,250,000	5,150,000

XML 32 R21.htm IDEA: XBRL DOCUMENT

Intellectual Property (Details) - USD ($)	May 10, 2019	Mar. 31, 2019	Jun. 30, 2018
Disclosure Intangible Assets Details Abstract
Intellectual Property		$ 2,293,770	$ 2,293,770
Accumulated Amortization		681,823	509,790
Intellectual Property, Net	$ 1,611,947	$ 1,611,947	$ 1,783,980

XML 33 R22.htm IDEA: XBRL DOCUMENT

Intellectual Property (Details 2) - USD ($)	May 10, 2019	Mar. 31, 2019	Jun. 30, 2018
Disclosure Intangible Assets Details 2Abstract
2019	$ 57,344
2020	229,377
2021	229,377
2022	229,377
2023	229,377
Thereafter	637,095
Intellectual Property, Net	$ 1,611,947	$ 1,611,947	$ 1,783,980

XML 34 R23.htm IDEA: XBRL DOCUMENT

Equity Transactions (Details) - Stock Option [Member]	9 Months Ended
Equity Transactions (Details) - Stock Option [Member]	Mar. 31, 2019 USD ($) $ / shares shares
Option Outstanding at beginning of period \| shares	5,150,000
Option Granted \| shares	2,100,000
Option Exercised \| shares
Option Outstanding at end of period \| shares	7,250,000
Option Excersiable at end of period \| shares	6,250,000
Outstanding Weighted Average Exercise Price at the beginning of period \| $ / shares	$ 0.12
Weighted Average Exercise Price, Granted \| $ / shares	0.04
Weighted Average Exercise Price, Exercised \| $ / shares
Outstanding Weighted Average Exercise Price at the end of period \| $ / shares	0.10
Excersiable Weighted Average Exercise Price at the end of period \| $ / shares	$ 0.10
Weighted Average Remaining Contractual Term at the beginning of period	5 years 9 months 18 days
Weighted Average Remaining Contractual Term, Granted	4 years 7 months 6 days
Weighted Average Remaining Contractual Term at the end	5 years 3 months 18 days
Excersiable Weighted Average Remaining Contractual Term at the end of period	5 years 3 months 18 days
Aggregate Intrinsic Value Outstanding at beginning of period \| $
Granted \| $	88,370
Options Exercised or Forfeited \| $
Aggregate Intrinsic Value Outstanding at end of period \| $	166,175
Aggregate Intrinsic Value Exercisable \| $

XML 35 R24.htm IDEA: XBRL DOCUMENT

Equity Transactions (Details 2) - Stock Option [Member] - $ / shares	9 Months Ended
	Mar. 31, 2019	Jun. 30, 2018
Exercise Price	$ 0.03
Option Outstanding	700,000
Weighted Average Contractual Life	4 years 9 months 18 days
Option Excersiable	700,000
Exercise Price	$ 0.05
Option Outstanding	1,300,000
Weighted Average Contractual Life	4 years 7 months 6 days
Option Excersiable	1,300,000
Exercise Price	$ 0.06
Option Outstanding	3,100,000
Weighted Average Contractual Life	6 years 10 months 24 days
Option Excersiable	2,100,000
Exercise Price	$ 0.07
Option Outstanding	100,000
Weighted Average Contractual Life	4 years 6 months
Option Excersiable	100,000
Exercise Price	$ 0.10
Option Outstanding	500,000
Weighted Average Contractual Life	3 years 9 months 18 days
Option Excersiable	500,000
Exercise Price	$ 0.20
Option Outstanding	200,000
Weighted Average Contractual Life	3 years 6 months
Option Excersiable	200,000
Exercise Price	$ 0.21
Option Outstanding	550,000
Weighted Average Contractual Life	3 years 1 month 6 days
Option Excersiable	550,000
Exercise Price	$ 0.22
Option Outstanding	100,000
Weighted Average Contractual Life	3 years
Option Excersiable	100,000
Exercise Price	$ 0.23
Option Outstanding	200,000
Weighted Average Contractual Life	3 years 4 months 24 days
Option Excersiable	200,000
Exercise Price	$ 0.25
Option Outstanding	500,000
Weighted Average Contractual Life	2 years 7 months 6 days
Option Excersiable	500,000
Option Outstanding	7,250,000	5,150,000
Weighted Average Contractual Life	5 years 9 months 18 days
Option Excersiable	6,250,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Equity Transactions (Details 3) - Warrant [Member]	9 Months Ended
Equity Transactions (Details 3) - Warrant [Member]	Mar. 31, 2019 USD ($) $ / shares shares
Warrant Outstanding at the beginning of the year \| shares	4,774,015
Warrant Granted \| shares	214,166,533
Warrant Expired \| shares
Warrant Exercised \| shares	(2,500,000)
Warrant Outstanding at the end of year \| shares	216,440,548
Weighted Average Exercise Price at the beginning of the year \| $ / shares	$ 0.29
Weighted Average Exercise Price, Granted \| $ / shares	0.02
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares	0.02
Weighted Average Exercise Price at the end of year \| $ / shares	$ 0.03
Weighted Average Remaining Life at the beginning of the year	5 years
Weighted Average Remaining Life, Granted	5 years 3 months 18 days
Weighted Average Remaining Life at the end of year	5 years 3 months 18 days
Aggregate Intrinsic Value, Granted \| $	$ 14,284,908
Aggregate Intrinsic Value Outstanding at end of period \| $	$ 14,284,908

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 38 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 89 144 1 false 16 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://nanoantibiotics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheet (Unaudited) Sheet http://nanoantibiotics.com/role/BalanceSheet Condensed Balance Sheet (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical) Sheet http://nanoantibiotics.com/role/BalanceSheetParenthetical Condensed Balance Sheet (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfStockholdersEquity Condensed Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Background Information Sheet http://nanoantibiotics.com/role/BackgroundInformation Background Information Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity Sheet http://nanoantibiotics.com/role/Liquidity Liquidity Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://nanoantibiotics.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Intellectual Property Sheet http://nanoantibiotics.com/role/IntellectualProperty Intellectual Property Notes 10 false false R11.htm 00000011 - Disclosure - Renegotiated Note Sheet http://nanoantibiotics.com/role/RenegotiatedNote Renegotiated Note Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://nanoantibiotics.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://nanoantibiotics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Equity Transactions Sheet http://nanoantibiotics.com/role/EquityTransactions Equity Transactions Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://nanoantibiotics.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://nanoantibiotics.com/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Significant Accounting Policies (Tables) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://nanoantibiotics.com/role/SignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Intellectual Property (Tables) Sheet http://nanoantibiotics.com/role/IntellectualPropertyTables Intellectual Property (Tables) Tables http://nanoantibiotics.com/role/IntellectualProperty 18 false false R19.htm 00000019 - Disclosure - Equity Transactions (Tables) Sheet http://nanoantibiotics.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://nanoantibiotics.com/role/EquityTransactions 19 false false R20.htm 00000020 - Disclosure - Significant Accounting Policies (Details) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables 20 false false R21.htm 00000021 - Disclosure - Intellectual Property (Details) Sheet http://nanoantibiotics.com/role/IntellectualPropertyDetails Intellectual Property (Details) Details http://nanoantibiotics.com/role/IntellectualPropertyTables 21 false false R22.htm 00000022 - Disclosure - Intellectual Property (Details 2) Sheet http://nanoantibiotics.com/role/IntellectualPropertyDetails2 Intellectual Property (Details 2) Details http://nanoantibiotics.com/role/IntellectualPropertyTables 22 false false R23.htm 00000023 - Disclosure - Equity Transactions (Details) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails Equity Transactions (Details) Details http://nanoantibiotics.com/role/EquityTransactionsTables 23 false false R24.htm 00000024 - Disclosure - Equity Transactions (Details 2) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails2 Equity Transactions (Details 2) Details http://nanoantibiotics.com/role/EquityTransactionsTables 24 false false R25.htm 00000025 - Disclosure - Equity Transactions (Details 3) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails3 Equity Transactions (Details 3) Details http://nanoantibiotics.com/role/EquityTransactionsTables 25 false false All Reports Book All Reports bivi-20190331.xml bivi-20190331.xsd bivi-20190331_cal.xml bivi-20190331_def.xml bivi-20190331_lab.xml bivi-20190331_pre.xml http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 42 0001520138-19-000143-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-19-000143-xbrl.zip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end